Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers
- 144 Downloads
Background and objectives
Fentanyl effervescent buccal tablets (FEBT) are designed to enhance the rate and efficiency of fentanyl absorption through the buccal mucosa. This study was undertaken to characterise the pharmacokinetics and assess the dose proportionality of FEBT in healthy volunteers within the potential therapeutic dose range.
Twenty-five healthy adults (mean age 33 years) completed a single-dose, randomised, open-label, four-dose, four-period, crossover study of FEBT. They were administered FEBT 200, 500, 810 or 1080μg. The subjects in this study were not opioid tolerant; therefore, naltrexone was administered to block any opioid receptor-mediated effects of fentanyl. Venous blood samples for measurement of serum fentanyl concentrations were obtained over 36 hours following dosing. Adverse events were recorded throughout the study.
The pharmacokinetics of FEBT were characterised by an absorption phase with a median time to reach maximum serum concentration (tmax) of 0.75–0.99 hours that was consistent irrespective of dose. Mean serum fentanyl concentrations exhibited a biexponential decline from peak after FEBT 200 and 500μg doses and a triexponential decline after FEBT 810 and 1080μg doses. The maximum serum concentration (Cmax) of fentanyl was proportional up to and including the 810μg dose. The increase in Cmax was 20% less than proportional at the 1080μg dose. Systemic exposure to fentanyl, as measured by the area under the serum concentration-time curve from time zero to infinity (AUC∞), increased proportionally with increasing doses of FEBT (200–1080μg). No serious adverse events were reported during the study.
The pharmacokinetics of FEBT were characterised by a high early fentanyl concentration as a result of absorption across the buccal mucosa of the oral cavity, which results in bypassing first-pass metabolism. This high early tmax contributed to enhanced early systemic fentanyl exposure. Maximum concentration and AUC∞ of FEBT increased in a dose-proportional manner from 200 to 810μg. This study provides preliminary pharmacokinetic data for FEBT across the potential therapeutic dose range.
KeywordsFentanyl Naltrexone Buccal Mucosa Breakthrough Pain Dose Proportionality
We would like to thank Dr James Kasicki and the staff of MDS Pharma Services for their assistance in carrying out this study.
This study was supported by Cephalon, Inc. (Frazer, PA, USA) and CIMA Labs, Inc. (Eden Prairie, MN, USA).
Mona Darwish, Mary Kirby and Jeffrey Thompson are employed by the sponsoring companies. Kenneth Tempero is a consultant for Cephalon, Inc. The authors have no other financial interests or conflicts of interest to disclose.
- 3.Fentanyl. In: Sweetman S, editor. Martindale: The complete drug reference. London: Pharmaceutical Press, Electronic version, Thomson MICROMEDEX, Greenwood Village, Colorado [Accessed 2005 Apr 26]Google Scholar
- 4.Barash PG, Cullen BF, Stoelting RK, editors. Clinical anesthesia. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001Google Scholar
- 5.Pather SI, Siebert JM, Hontz J, et al. Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system [online]. Available from URL: http://drugdeliverytech.com/cgi-bin/issues.cgi?idIssue=1 [Accessed 2001 Jun 23]
- 10.Center for Drug Evaluation and Research FDA. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products: general considerations [online]. Available from URL: http://www.fda.gov/cder/guidance/5356fnl.pdf [Accessed 2003 Jun 4]